SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today new positive data from the late-breaking presentation at ASN Kidney Week 2026 in Denver, Colorado.

The primary exposure-defined analysis at Day 90 resulted in a statistically significant increase in survival of the QUELIMMUNE (SCD-PED) cohort achieving 65.1% survival compared to 47.4% for the KID cohort (P = 0.043), representing more than double the odds of survival for QUELIMMUNE (SCD-PED)-treated patients (odds ratio [OR] 2.07; 95% confidence interval, [CI] 1.04-4.11). The Bayesian probability of higher survival in QUELIMMUNE (SCD-PED) patients was 98.2%. A second landmark sensitivity analysis favored the QUELIMMUNE (SCD-PED) cohort achieving 63.8% Day 90 survival, an increase of 15.1 percentage points over the KID cohort survival of 48.7% (P= 0.074), representing 86% higher estimated odds of survival (OR 1.86; 95% CI, 0.96-3.60). The Bayesian probability of higher survival in the QUELIMMUNE (SCD-PED) landmark cohort was 96.8%.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.